U.S. markets closed

Entasis Therapeutics Holdings Inc. (ETTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.1000+0.0900 (+2.99%)
At close: 4:00PM EST

3.1000 0.00 (0.00%)
After hours: 5:27PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close3.0100
Open3.0200
Bid2.9000 x 1000
Ask3.1000 x 2200
Day's Range2.9001 - 3.1000
52 Week Range1.5800 - 5.6400
Volume615,246
Avg. Volume754,464
Market Cap109.974M
Beta (5Y Monthly)2.10
PE Ratio (TTM)N/A
EPS (TTM)-2.9220
Earnings DateMar 09, 2021 - Mar 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference
    GlobeNewswire

    Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference

    WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021. The Company’s presentation will be available on demand starting Monday, January 11th, 2021 at 6:00 AM ET, to those attending the conference virtually.About Entasis Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). For more information, visit www.entasistx.com.Entasis Company Contact Kyle Dow Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.comInvestor Relations Contact James Salierno The Ruth Group (646) 536-7028 jsalierno@theruthgroup.comMedia Contact Annika Parrish The Ruth Group (720) 412-9042 aparrish@theruthgroup.com

  • We Think Entasis Therapeutics Holdings (NASDAQ:ETTX) Needs To Drive Business Growth Carefully
    Simply Wall St.

    We Think Entasis Therapeutics Holdings (NASDAQ:ETTX) Needs To Drive Business Growth Carefully

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

  • Entasis Therapeutics to Participate in A.G.P.’s Virtual Healthcare Symposium
    GlobeNewswire

    Entasis Therapeutics to Participate in A.G.P.’s Virtual Healthcare Symposium

    WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that members of management will participate in A.G.P.’s Virtual Healthcare Symposium on Thursday, November 19th, 2020. The event will consist of 1-on-1 virtual investor meetings. Investors attending the conference virtually who are interested in meeting with Company management should contact their A.G.P. representative.About EntasisEntasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). For more information, visit www.entasistx.com.Entasis Company Contact          Kyle Dow Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.comInvestor Relations Contact James Salierno The Ruth Group (646) 536-7028 jsalierno@theruthgroup.comMedia Contact Annika Parrish The Ruth Group (720) 412-9042 aparrish@theruthgroup.com